Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.

  title={Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.},
  author={Dieter Huhn and Christoph von Schilling and Martin Wilhelm and Anthony D. Ho and Mohamed Hallek and Rolf Kuse and W Knauf and U. Riedel and Axel Hinke and Stefanie Srock and Stefan Serke and Christian Peschel and Berthold Emmerich},
  volume={98 5},
Rituximab (IDEC-C2B8) is a chimeric antibody that binds to the B-cell surface antigen CD20. Rituximab has significant activity in follicular non-Hodgkin lymphomas. Much less is known about the effects in chronic lymphocytic leukemia (CLL). We have initiated a phase II trial to evaluate the efficacy and safety of rituximab in patients with CD20+ pretreated CLL. To avoid the rituximab-associated toxicity, we restricted the tumor cell load, as measured by the number of circulating lymphocytes and… CONTINUE READING